nodes	percent_of_prediction	percent_of_DWPC	metapath
Haloperidol—SIGMAR1—amyotrophic lateral sclerosis	0.526	1	CbGaD
Haloperidol—CYP1A1—Riluzole—amyotrophic lateral sclerosis	0.192	0.691	CbGbCtD
Haloperidol—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.0858	0.309	CbGbCtD
Haloperidol—Motor dysfunction—Riluzole—amyotrophic lateral sclerosis	0.0103	0.102	CcSEcCtD
Haloperidol—HTR2A—phrenic nerve—amyotrophic lateral sclerosis	0.00481	0.0953	CbGeAlD
Haloperidol—Trismus—Riluzole—amyotrophic lateral sclerosis	0.00447	0.0444	CcSEcCtD
Haloperidol—Priapism—Riluzole—amyotrophic lateral sclerosis	0.00309	0.0307	CcSEcCtD
Haloperidol—GRIN2B—nerve—amyotrophic lateral sclerosis	0.00275	0.0544	CbGeAlD
Haloperidol—Hypothermia—Riluzole—amyotrophic lateral sclerosis	0.00266	0.0264	CcSEcCtD
Haloperidol—Body temperature decreased—Riluzole—amyotrophic lateral sclerosis	0.00266	0.0264	CcSEcCtD
Haloperidol—HTR1B—cranial nerve—amyotrophic lateral sclerosis	0.00261	0.0516	CbGeAlD
Haloperidol—HTR1D—cranial nerve—amyotrophic lateral sclerosis	0.00252	0.05	CbGeAlD
Haloperidol—Libido increased—Riluzole—amyotrophic lateral sclerosis	0.00245	0.0244	CcSEcCtD
Haloperidol—Hypokinesia—Riluzole—amyotrophic lateral sclerosis	0.00221	0.022	CcSEcCtD
Haloperidol—Mazindol—SIGMAR1—amyotrophic lateral sclerosis	0.0021	1	CrCbGaD
Haloperidol—GRIN2B—hindbrain—amyotrophic lateral sclerosis	0.00206	0.0407	CbGeAlD
Haloperidol—Extrapyramidal disorder—Riluzole—amyotrophic lateral sclerosis	0.00198	0.0197	CcSEcCtD
Haloperidol—Ventricular fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00195	0.0194	CcSEcCtD
Haloperidol—Endocrine disorder—Riluzole—amyotrophic lateral sclerosis	0.0018	0.0179	CcSEcCtD
Haloperidol—Breast pain—Riluzole—amyotrophic lateral sclerosis	0.00171	0.017	CcSEcCtD
Haloperidol—Amenorrhoea—Riluzole—amyotrophic lateral sclerosis	0.0017	0.0169	CcSEcCtD
Haloperidol—Musculoskeletal stiffness—Riluzole—amyotrophic lateral sclerosis	0.00166	0.0165	CcSEcCtD
Haloperidol—DRD1—nerve—amyotrophic lateral sclerosis	0.00165	0.0326	CbGeAlD
Haloperidol—Leukocytosis—Riluzole—amyotrophic lateral sclerosis	0.00159	0.0158	CcSEcCtD
Haloperidol—Cataract—Riluzole—amyotrophic lateral sclerosis	0.00157	0.0156	CcSEcCtD
Haloperidol—Gait disturbance—Riluzole—amyotrophic lateral sclerosis	0.00153	0.0152	CcSEcCtD
Haloperidol—Ventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00149	0.0148	CcSEcCtD
Haloperidol—Injection site reaction—Riluzole—amyotrophic lateral sclerosis	0.00148	0.0147	CcSEcCtD
Haloperidol—Hypertonia—Riluzole—amyotrophic lateral sclerosis	0.00131	0.013	CcSEcCtD
Haloperidol—Euphoric mood—Riluzole—amyotrophic lateral sclerosis	0.00128	0.0127	CcSEcCtD
Haloperidol—HTR2A—cranial nerve—amyotrophic lateral sclerosis	0.00125	0.0248	CbGeAlD
Haloperidol—Hepatic function abnormal—Riluzole—amyotrophic lateral sclerosis	0.00124	0.0123	CcSEcCtD
Haloperidol—HTR2A—pons—amyotrophic lateral sclerosis	0.00124	0.0245	CbGeAlD
Haloperidol—Photosensitivity—Riluzole—amyotrophic lateral sclerosis	0.00123	0.0123	CcSEcCtD
Haloperidol—GRIN2B—brainstem—amyotrophic lateral sclerosis	0.00118	0.0233	CbGeAlD
Haloperidol—Libido decreased—Riluzole—amyotrophic lateral sclerosis	0.00117	0.0116	CcSEcCtD
Haloperidol—Dermatitis exfoliative—Riluzole—amyotrophic lateral sclerosis	0.00115	0.0114	CcSEcCtD
Haloperidol—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.00109	0.0108	CcSEcCtD
Haloperidol—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.00108	0.0107	CcSEcCtD
Haloperidol—Psychotic disorder—Riluzole—amyotrophic lateral sclerosis	0.00106	0.0105	CcSEcCtD
Haloperidol—HTR2A—hindlimb—amyotrophic lateral sclerosis	0.00106	0.0209	CbGeAlD
Haloperidol—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.00105	0.0104	CcSEcCtD
Haloperidol—Cardiac arrest—Riluzole—amyotrophic lateral sclerosis	0.00103	0.0102	CcSEcCtD
Haloperidol—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.00103	0.0102	CcSEcCtD
Haloperidol—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.001	0.00993	CcSEcCtD
Haloperidol—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.00099	0.00982	CcSEcCtD
Haloperidol—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.000979	0.00972	CcSEcCtD
Haloperidol—DRD2—nerve—amyotrophic lateral sclerosis	0.000974	0.0193	CbGeAlD
Haloperidol—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.000937	0.0093	CcSEcCtD
Haloperidol—HTR2A—appendage—amyotrophic lateral sclerosis	0.000906	0.0179	CbGeAlD
Haloperidol—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.000889	0.00883	CcSEcCtD
Haloperidol—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.000876	0.00869	CcSEcCtD
Haloperidol—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.000863	0.00856	CcSEcCtD
Haloperidol—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.000855	0.00849	CcSEcCtD
Haloperidol—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.000852	0.00846	CcSEcCtD
Haloperidol—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.000847	0.00841	CcSEcCtD
Haloperidol—Depression—Riluzole—amyotrophic lateral sclerosis	0.000833	0.00827	CcSEcCtD
Haloperidol—HTR2A—peripheral nervous system—amyotrophic lateral sclerosis	0.000824	0.0163	CbGeAlD
Haloperidol—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.000814	0.00808	CcSEcCtD
Haloperidol—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00079	0.00784	CcSEcCtD
Haloperidol—H1F0—embryo—amyotrophic lateral sclerosis	0.000782	0.0155	CbGeAlD
Haloperidol—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.000779	0.00774	CcSEcCtD
Haloperidol—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.00075	0.00744	CcSEcCtD
Haloperidol—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.000746	0.0074	CcSEcCtD
Haloperidol—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00074	0.00735	CcSEcCtD
Haloperidol—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.000737	0.00731	CcSEcCtD
Haloperidol—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.000735	0.00729	CcSEcCtD
Haloperidol—GRIN2B—spinal cord—amyotrophic lateral sclerosis	0.000733	0.0145	CbGeAlD
Haloperidol—DRD2—hindbrain—amyotrophic lateral sclerosis	0.000729	0.0144	CbGeAlD
Haloperidol—DRD1—brainstem—amyotrophic lateral sclerosis	0.000707	0.014	CbGeAlD
Haloperidol—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.000701	0.00695	CcSEcCtD
Haloperidol—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.000696	0.00691	CcSEcCtD
Haloperidol—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00068	0.00675	CcSEcCtD
Haloperidol—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.000677	0.00672	CcSEcCtD
Haloperidol—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000676	0.00671	CcSEcCtD
Haloperidol—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.000662	0.00658	CcSEcCtD
Haloperidol—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.000657	0.00652	CcSEcCtD
Haloperidol—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.000653	0.00648	CcSEcCtD
Haloperidol—HTR2A—nerve—amyotrophic lateral sclerosis	0.000642	0.0127	CbGeAlD
Haloperidol—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.000627	0.00623	CcSEcCtD
Haloperidol—GRIN2B—nervous system—amyotrophic lateral sclerosis	0.000618	0.0122	CbGeAlD
Haloperidol—Tremor—Riluzole—amyotrophic lateral sclerosis	0.000611	0.00607	CcSEcCtD
Haloperidol—CBR1—medulla oblongata—amyotrophic lateral sclerosis	0.00061	0.0121	CbGeAlD
Haloperidol—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.000603	0.00599	CcSEcCtD
Haloperidol—Agitation—Riluzole—amyotrophic lateral sclerosis	0.0006	0.00595	CcSEcCtD
Haloperidol—GRIN2B—central nervous system—amyotrophic lateral sclerosis	0.000595	0.0118	CbGeAlD
Haloperidol—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.000586	0.00582	CcSEcCtD
Haloperidol—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.000584	0.0058	CcSEcCtD
Haloperidol—GRIN2B—cerebellum—amyotrophic lateral sclerosis	0.000581	0.0115	CbGeAlD
Haloperidol—HTR1B—brainstem—amyotrophic lateral sclerosis	0.000573	0.0114	CbGeAlD
Haloperidol—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.000565	0.00561	CcSEcCtD
Haloperidol—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.000563	0.00559	CcSEcCtD
Haloperidol—DRD4—brain—amyotrophic lateral sclerosis	0.000563	0.0111	CbGeAlD
Haloperidol—HTR1D—brainstem—amyotrophic lateral sclerosis	0.000555	0.011	CbGeAlD
Haloperidol—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.000554	0.0055	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.000552	0.00548	CcSEcCtD
Haloperidol—CBR1—spinal cord—amyotrophic lateral sclerosis	0.000544	0.0108	CbGeAlD
Haloperidol—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.000543	0.00539	CcSEcCtD
Haloperidol—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.000537	0.00533	CcSEcCtD
Haloperidol—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.000533	0.00529	CcSEcCtD
Haloperidol—Oedema—Riluzole—amyotrophic lateral sclerosis	0.000533	0.00529	CcSEcCtD
Haloperidol—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.000522	0.00518	CcSEcCtD
Haloperidol—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.000521	0.00518	CcSEcCtD
Haloperidol—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00052	0.00516	CcSEcCtD
Haloperidol—DRD3—nervous system—amyotrophic lateral sclerosis	0.000518	0.0103	CbGeAlD
Haloperidol—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.000517	0.00514	CcSEcCtD
Haloperidol—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.000515	0.00511	CcSEcCtD
Haloperidol—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.000508	0.00504	CcSEcCtD
Haloperidol—H1F0—medulla oblongata—amyotrophic lateral sclerosis	0.0005	0.00989	CbGeAlD
Haloperidol—DRD3—central nervous system—amyotrophic lateral sclerosis	0.000498	0.00987	CbGeAlD
Haloperidol—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.000498	0.00494	CcSEcCtD
Haloperidol—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.000482	0.00478	CcSEcCtD
Haloperidol—HTR2A—hindbrain—amyotrophic lateral sclerosis	0.000481	0.00953	CbGeAlD
Haloperidol—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000475	0.00471	CcSEcCtD
Haloperidol—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.000473	0.0047	CcSEcCtD
Haloperidol—GRIN2B—brain—amyotrophic lateral sclerosis	0.000472	0.00935	CbGeAlD
Haloperidol—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000469	0.00465	CcSEcCtD
Haloperidol—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000463	0.0046	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00046	0.00456	CcSEcCtD
Haloperidol—CBR1—nervous system—amyotrophic lateral sclerosis	0.000458	0.00907	CbGeAlD
Haloperidol—Constipation—Riluzole—amyotrophic lateral sclerosis	0.000455	0.00452	CcSEcCtD
Haloperidol—H1F0—spinal cord—amyotrophic lateral sclerosis	0.000445	0.00882	CbGeAlD
Haloperidol—CBR1—central nervous system—amyotrophic lateral sclerosis	0.000441	0.00873	CbGeAlD
Haloperidol—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.000439	0.00436	CcSEcCtD
Haloperidol—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.000438	0.00868	CbGeAlD
Haloperidol—CBR1—cerebellum—amyotrophic lateral sclerosis	0.000431	0.00854	CbGeAlD
Haloperidol—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.000423	0.0042	CcSEcCtD
Haloperidol—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000421	0.00418	CcSEcCtD
Haloperidol—DRD2—brainstem—amyotrophic lateral sclerosis	0.000418	0.00828	CbGeAlD
Haloperidol—DRD3—brain—amyotrophic lateral sclerosis	0.000396	0.00784	CbGeAlD
Haloperidol—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000392	0.0039	CcSEcCtD
Haloperidol—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000377	0.00374	CcSEcCtD
Haloperidol—H1F0—nervous system—amyotrophic lateral sclerosis	0.000375	0.00743	CbGeAlD
Haloperidol—DRD1—nervous system—amyotrophic lateral sclerosis	0.000371	0.00734	CbGeAlD
Haloperidol—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000364	0.00362	CcSEcCtD
Haloperidol—H1F0—central nervous system—amyotrophic lateral sclerosis	0.000361	0.00716	CbGeAlD
Haloperidol—SIGMAR1—medulla oblongata—amyotrophic lateral sclerosis	0.000361	0.00715	CbGeAlD
Haloperidol—DRD1—central nervous system—amyotrophic lateral sclerosis	0.000357	0.00707	CbGeAlD
Haloperidol—HTR1B—spinal cord—amyotrophic lateral sclerosis	0.000356	0.00706	CbGeAlD
Haloperidol—H1F0—cerebellum—amyotrophic lateral sclerosis	0.000353	0.007	CbGeAlD
Haloperidol—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000352	0.0035	CcSEcCtD
Haloperidol—CBR1—brain—amyotrophic lateral sclerosis	0.00035	0.00693	CbGeAlD
Haloperidol—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000339	0.00336	CcSEcCtD
Haloperidol—Rash—Riluzole—amyotrophic lateral sclerosis	0.000336	0.00333	CcSEcCtD
Haloperidol—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000336	0.00333	CcSEcCtD
Haloperidol—Headache—Riluzole—amyotrophic lateral sclerosis	0.000334	0.00331	CcSEcCtD
Haloperidol—SIGMAR1—spinal cord—amyotrophic lateral sclerosis	0.000322	0.00637	CbGeAlD
Haloperidol—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000316	0.00314	CcSEcCtD
Haloperidol—HTR2A—embryo—amyotrophic lateral sclerosis	0.000301	0.00596	CbGeAlD
Haloperidol—HTR1B—nervous system—amyotrophic lateral sclerosis	0.0003	0.00595	CbGeAlD
Haloperidol—HTR1D—nervous system—amyotrophic lateral sclerosis	0.000291	0.00576	CbGeAlD
Haloperidol—HTR1B—central nervous system—amyotrophic lateral sclerosis	0.000289	0.00573	CbGeAlD
Haloperidol—KCNH2—medulla oblongata—amyotrophic lateral sclerosis	0.000287	0.00569	CbGeAlD
Haloperidol—H1F0—brain—amyotrophic lateral sclerosis	0.000287	0.00568	CbGeAlD
Haloperidol—DRD1—brain—amyotrophic lateral sclerosis	0.000283	0.00561	CbGeAlD
Haloperidol—HTR1D—central nervous system—amyotrophic lateral sclerosis	0.00028	0.00554	CbGeAlD
Haloperidol—HTR2A—brainstem—amyotrophic lateral sclerosis	0.000276	0.00546	CbGeAlD
Haloperidol—HTR2B—nervous system—amyotrophic lateral sclerosis	0.00027	0.00536	CbGeAlD
Haloperidol—HTR2B—central nervous system—amyotrophic lateral sclerosis	0.00026	0.00516	CbGeAlD
Haloperidol—KCNH2—spinal cord—amyotrophic lateral sclerosis	0.000256	0.00507	CbGeAlD
Haloperidol—SIGMAR1—cerebellum—amyotrophic lateral sclerosis	0.000255	0.00505	CbGeAlD
Haloperidol—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.000251	0.00497	CbGeAlD
Haloperidol—HTR1B—brain—amyotrophic lateral sclerosis	0.00023	0.00455	CbGeAlD
Haloperidol—HTR1D—brain—amyotrophic lateral sclerosis	0.000222	0.0044	CbGeAlD
Haloperidol—DRD2—nervous system—amyotrophic lateral sclerosis	0.000219	0.00434	CbGeAlD
Haloperidol—KCNH2—nervous system—amyotrophic lateral sclerosis	0.000216	0.00427	CbGeAlD
Haloperidol—DRD2—central nervous system—amyotrophic lateral sclerosis	0.000211	0.00418	CbGeAlD
Haloperidol—KCNH2—central nervous system—amyotrophic lateral sclerosis	0.000208	0.00411	CbGeAlD
Haloperidol—SIGMAR1—brain—amyotrophic lateral sclerosis	0.000207	0.0041	CbGeAlD
Haloperidol—HTR2B—brain—amyotrophic lateral sclerosis	0.000207	0.00409	CbGeAlD
Haloperidol—DRD2—cerebellum—amyotrophic lateral sclerosis	0.000206	0.00408	CbGeAlD
Haloperidol—KCNH2—cerebellum—amyotrophic lateral sclerosis	0.000203	0.00402	CbGeAlD
Haloperidol—ABCB1—embryo—amyotrophic lateral sclerosis	0.000197	0.0039	CbGeAlD
Haloperidol—HTR2A—medulla oblongata—amyotrophic lateral sclerosis	0.000192	0.00381	CbGeAlD
Haloperidol—CYP1A1—nervous system—amyotrophic lateral sclerosis	0.000182	0.00361	CbGeAlD
Haloperidol—CYP1A1—central nervous system—amyotrophic lateral sclerosis	0.000175	0.00347	CbGeAlD
Haloperidol—HRH1—nervous system—amyotrophic lateral sclerosis	0.000173	0.00342	CbGeAlD
Haloperidol—HTR2A—spinal cord—amyotrophic lateral sclerosis	0.000171	0.00339	CbGeAlD
Haloperidol—DRD2—brain—amyotrophic lateral sclerosis	0.000167	0.00331	CbGeAlD
Haloperidol—HRH1—central nervous system—amyotrophic lateral sclerosis	0.000166	0.0033	CbGeAlD
Haloperidol—KCNH2—brain—amyotrophic lateral sclerosis	0.000165	0.00327	CbGeAlD
Haloperidol—HTR2A—nervous system—amyotrophic lateral sclerosis	0.000144	0.00286	CbGeAlD
Haloperidol—CYP1A1—brain—amyotrophic lateral sclerosis	0.000139	0.00276	CbGeAlD
Haloperidol—HTR2A—central nervous system—amyotrophic lateral sclerosis	0.000139	0.00275	CbGeAlD
Haloperidol—HTR2A—cerebellum—amyotrophic lateral sclerosis	0.000136	0.00269	CbGeAlD
Haloperidol—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000134	0.00265	CbGeAlD
Haloperidol—HRH1—brain—amyotrophic lateral sclerosis	0.000132	0.00262	CbGeAlD
Haloperidol—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.000132	0.00261	CbGeAlD
Haloperidol—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000129	0.00255	CbGeAlD
Haloperidol—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.000127	0.00251	CbGeAlD
Haloperidol—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.000126	0.00249	CbGeAlD
Haloperidol—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.000124	0.00245	CbGeAlD
Haloperidol—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.000112	0.00222	CbGeAlD
Haloperidol—HTR2A—brain—amyotrophic lateral sclerosis	0.00011	0.00219	CbGeAlD
Haloperidol—CYP2D6—brain—amyotrophic lateral sclerosis	0.000101	0.00199	CbGeAlD
Haloperidol—ABCB1—nervous system—amyotrophic lateral sclerosis	9.46e-05	0.00187	CbGeAlD
Haloperidol—ABCB1—central nervous system—amyotrophic lateral sclerosis	9.11e-05	0.0018	CbGeAlD
Haloperidol—ABCB1—cerebellum—amyotrophic lateral sclerosis	8.91e-05	0.00176	CbGeAlD
Haloperidol—ABCB1—brain—amyotrophic lateral sclerosis	7.23e-05	0.00143	CbGeAlD
Haloperidol—CYP2C19—Metabolism—DAO—amyotrophic lateral sclerosis	1.43e-05	0.000334	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	1.42e-05	0.000334	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	1.41e-05	0.00033	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—VAPA—amyotrophic lateral sclerosis	1.41e-05	0.000329	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	1.4e-05	0.000328	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	1.4e-05	0.000327	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PLB1—amyotrophic lateral sclerosis	1.4e-05	0.000327	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	1.39e-05	0.000326	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	1.38e-05	0.000323	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	1.35e-05	0.000316	CbGpPWpGaD
Haloperidol—HTR1D—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	1.34e-05	0.000314	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	1.34e-05	0.000314	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	1.33e-05	0.000311	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PLB1—amyotrophic lateral sclerosis	1.32e-05	0.000309	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	1.32e-05	0.000309	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	1.31e-05	0.000308	CbGpPWpGaD
Haloperidol—HTR1B—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	1.31e-05	0.000308	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	1.31e-05	0.000307	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.31e-05	0.000306	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	1.3e-05	0.000304	CbGpPWpGaD
Haloperidol—DRD4—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	1.29e-05	0.000303	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—GSR—amyotrophic lateral sclerosis	1.29e-05	0.000302	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—VCP—amyotrophic lateral sclerosis	1.27e-05	0.000297	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	1.27e-05	0.000297	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—VCP—amyotrophic lateral sclerosis	1.25e-05	0.000293	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	1.25e-05	0.000292	CbGpPWpGaD
Haloperidol—HTR2B—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	1.23e-05	0.000289	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	1.23e-05	0.000288	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	1.23e-05	0.000288	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—GSR—amyotrophic lateral sclerosis	1.22e-05	0.000285	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.22e-05	0.000285	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	1.21e-05	0.000283	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	1.21e-05	0.000283	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	1.2e-05	0.00028	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	1.2e-05	0.00028	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.19e-05	0.000279	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	1.19e-05	0.000278	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	1.19e-05	0.000278	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	1.18e-05	0.000276	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.17e-05	0.000275	CbGpPWpGaD
Haloperidol—DRD1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	1.16e-05	0.000272	CbGpPWpGaD
Haloperidol—DRD3—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	1.15e-05	0.000269	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.13e-05	0.000265	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.12e-05	0.000262	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—DAO—amyotrophic lateral sclerosis	1.11e-05	0.00026	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	1.11e-05	0.00026	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	1.11e-05	0.00026	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.11e-05	0.00026	CbGpPWpGaD
Haloperidol—DRD2—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	1.1e-05	0.000259	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	1.09e-05	0.000256	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.09e-05	0.000256	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.09e-05	0.000255	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	1.08e-05	0.000254	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PLB1—amyotrophic lateral sclerosis	1.08e-05	0.000253	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	1.08e-05	0.000253	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	1.07e-05	0.000252	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	1.07e-05	0.000251	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.06e-05	0.000249	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	1.06e-05	0.000249	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	1.06e-05	0.000248	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—CHAT—amyotrophic lateral sclerosis	1.06e-05	0.000248	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.06e-05	0.000247	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	1.05e-05	0.000247	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.04e-05	0.000244	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.04e-05	0.000244	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.04e-05	0.000244	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.02e-05	0.00024	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.01e-05	0.000237	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.01e-05	0.000236	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—CHAT—amyotrophic lateral sclerosis	1e-05	0.000234	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—GSR—amyotrophic lateral sclerosis	9.97e-06	0.000233	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	9.94e-06	0.000233	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	9.9e-06	0.000232	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	9.85e-06	0.000231	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	9.82e-06	0.00023	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	9.77e-06	0.000229	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	9.75e-06	0.000228	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	9.73e-06	0.000228	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	9.69e-06	0.000227	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	9.48e-06	0.000222	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	9.42e-06	0.000221	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.36e-06	0.000219	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	9.3e-06	0.000218	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	9.21e-06	0.000216	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	9.17e-06	0.000215	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	9.13e-06	0.000214	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	9.09e-06	0.000213	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	9.09e-06	0.000213	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	9.08e-06	0.000213	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	9.02e-06	0.000211	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	8.88e-06	0.000208	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	8.86e-06	0.000208	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	8.78e-06	0.000206	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	8.77e-06	0.000205	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	8.66e-06	0.000203	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	8.66e-06	0.000203	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	8.64e-06	0.000202	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	8.62e-06	0.000202	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.6e-06	0.000201	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	8.57e-06	0.000201	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	8.48e-06	0.000199	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	8.42e-06	0.000197	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	8.34e-06	0.000195	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	8.28e-06	0.000194	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—CHAT—amyotrophic lateral sclerosis	8.19e-06	0.000192	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	8.14e-06	0.000191	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	7.99e-06	0.000187	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—C3—amyotrophic lateral sclerosis	7.98e-06	0.000187	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	7.97e-06	0.000187	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	7.96e-06	0.000186	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.87e-06	0.000184	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—C3—amyotrophic lateral sclerosis	7.85e-06	0.000184	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	7.84e-06	0.000184	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	7.83e-06	0.000183	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	7.77e-06	0.000182	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	7.53e-06	0.000176	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	7.51e-06	0.000176	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	7.49e-06	0.000175	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	7.47e-06	0.000175	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	7.47e-06	0.000175	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	7.42e-06	0.000174	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	7.41e-06	0.000174	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	7.3e-06	0.000171	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	7.28e-06	0.000171	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	7.24e-06	0.000169	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—C3—amyotrophic lateral sclerosis	7.19e-06	0.000168	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	7.12e-06	0.000167	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—APOE—amyotrophic lateral sclerosis	7.08e-06	0.000166	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	7.07e-06	0.000166	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	7.06e-06	0.000165	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—C3—amyotrophic lateral sclerosis	7.04e-06	0.000165	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	6.97e-06	0.000163	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	6.96e-06	0.000163	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—C3—amyotrophic lateral sclerosis	6.93e-06	0.000162	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	6.84e-06	0.00016	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	6.83e-06	0.00016	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	6.81e-06	0.00016	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—APOE—amyotrophic lateral sclerosis	6.7e-06	0.000157	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	6.62e-06	0.000155	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—C3—amyotrophic lateral sclerosis	6.62e-06	0.000155	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—APOE—amyotrophic lateral sclerosis	6.56e-06	0.000154	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	6.52e-06	0.000153	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	6.5e-06	0.000152	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	6.5e-06	0.000152	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—APOE—amyotrophic lateral sclerosis	6.45e-06	0.000151	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	6.38e-06	0.000149	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	6.26e-06	0.000146	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—C3—amyotrophic lateral sclerosis	6.24e-06	0.000146	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—APOE—amyotrophic lateral sclerosis	6.16e-06	0.000144	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—C3—amyotrophic lateral sclerosis	6.16e-06	0.000144	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	6e-06	0.00014	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—APOE—amyotrophic lateral sclerosis	5.95e-06	0.000139	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	5.82e-06	0.000136	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	5.81e-06	0.000136	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—APOE—amyotrophic lateral sclerosis	5.73e-06	0.000134	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—GSTP1—amyotrophic lateral sclerosis	5.69e-06	0.000133	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	5.67e-06	0.000133	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	5.58e-06	0.000131	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	5.57e-06	0.00013	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	5.53e-06	0.00013	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	5.42e-06	0.000127	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	5.38e-06	0.000126	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	5.33e-06	0.000125	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	5.33e-06	0.000125	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	5.25e-06	0.000123	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	5.23e-06	0.000123	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.23e-06	0.000122	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	5.12e-06	0.00012	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	5.09e-06	0.000119	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.94e-06	0.000116	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	4.92e-06	0.000115	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.85e-06	0.000114	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.8e-06	0.000112	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.74e-06	0.000111	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.71e-06	0.00011	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	4.67e-06	0.000109	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.64e-06	0.000109	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—C3—amyotrophic lateral sclerosis	4.63e-06	0.000108	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.4e-06	0.000103	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.39e-06	0.000103	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.32e-06	0.000101	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	4.31e-06	0.000101	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—APOE—amyotrophic lateral sclerosis	4.3e-06	0.000101	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.29e-06	0.000101	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.26e-06	9.98e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.17e-06	9.77e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.1e-06	9.61e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.08e-06	9.55e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—APOE—amyotrophic lateral sclerosis	4.07e-06	9.52e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.05e-06	9.48e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.04e-06	9.47e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.03e-06	9.43e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.01e-06	9.4e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	3.99e-06	9.34e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.95e-06	9.24e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.94e-06	9.23e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.92e-06	9.18e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.88e-06	9.08e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.72e-06	8.71e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.7e-06	8.67e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.7e-06	8.65e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.69e-06	8.63e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.65e-06	8.54e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.62e-06	8.49e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.62e-06	8.47e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.57e-06	8.35e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	3.56e-06	8.33e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.54e-06	8.29e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.49e-06	8.18e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.48e-06	8.16e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.45e-06	8.07e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.43e-06	8.03e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—APOE—amyotrophic lateral sclerosis	3.33e-06	7.79e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.33e-06	7.79e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	3.25e-06	7.6e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.15e-06	7.38e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.14e-06	7.34e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.09e-06	7.25e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	3.06e-06	7.17e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	3.03e-06	7.1e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.95e-06	6.91e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.79e-06	6.53e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.79e-06	6.52e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.75e-06	6.43e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.74e-06	6.41e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.73e-06	6.4e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.67e-06	6.26e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.65e-06	6.2e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.64e-06	6.17e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.63e-06	6.16e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.59e-06	6.08e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	2.59e-06	6.07e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.59e-06	6.06e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.51e-06	5.88e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.43e-06	5.69e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.37e-06	5.55e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.37e-06	5.54e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.34e-06	5.47e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.33e-06	5.46e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.32e-06	5.44e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.28e-06	5.34e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.22e-06	5.21e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.1e-06	4.91e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.08e-06	4.87e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	2e-06	4.69e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.79e-06	4.19e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.78e-06	4.16e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.76e-06	4.12e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.76e-06	4.11e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.37e-06	3.21e-05	CbGpPWpGaD
